 This multicenter, open-label, randomized, parallel study was designed to evaluate whether a single fixed-dose subcutaneous SC administration of pegfilgrastim or daily administration of Filgrastim for absolute neutrophil count ANC support would assist in allowing the planned dose-on-time PDOT of cyclophosphamide, doxorubicin, vincristine, prednisolone CHOP chemotherapy with Rituximab every 14 days in subjects with aggressive B-cell Non-Hodgkins Lymphoma by reducing the duration of neutropenia and incidence of febrile neutropenia. 